Skip Navigation Archive: U.S. Department of Health and Human Services U.S. Department of Health and Human Services
Archive: Agency for Healthcare Research Quality
Archival print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

  • Publication # 13-RA004

The March 2014 issue of Research Activities was the last issue of the monthly newsletter. AHRQ is transitioning to a new quarterly thematic publication that will provide longer, more in-depth analyses of individual topics related to AHRQ’s four priority areas. This new publication will be available online  in the Fall.

Research Activities readers will still be able to access published studies by AHRQ and AHRQ-supported researchers on the AHRQ Research Studies Web page, which will be online later this Spring. Studies can be accessed by first author, publication date, and key word.

Thanks to all our readers over the years who have told us how much they have enjoyed the newsletter. We hope our new quarterly publication will be equally useful in learning more about AHRQ and the field of health services research!

For questions, please contact Research Activities managing editor, Gail Makulowich, at or at 301-427-1711.

Four drugs to treat chronic heart failure found similarly effective

Comparative Effectiveness Research

Thanks to their tolerability profiles, angiotensin receptor blockers (ARBs) are becoming the preferred medications to treat chronic heart failure (CHF). A new study that compared four ARBs to determine their ability to reduce mortality in patients with CHF found them to be similarly effective at reducing the death rate in everyday clinical practice.

The researchers identified 1,536 veterans with CHF from electronic medical records, with review of their medical charts providing additional clinical data. They categorized patients into one of four groups based on the ARB initially used: candesartan, valsartan, losartan, and irbesartan. They measured time to death during the study's 2-year period.

Of the 4 ARBs, irbesartan was the most popular, taken by 55.21 percent of patients. This was followed by losartan, candesartan, and valsartan. There was significant geographic variation in use of ARBs. For example, Midwest patients tended to use losartan and candesartan. However, no patients from the northeast were on candesartan and only two patients in the West were on valsartan. Concurrent hospitalization rates were higher for patients receiving irbesartan; valsartan had the lowest rate.

After the researchers controlled for numerous demographic and clinical factors, they found no statistically significant difference among the four ARBs in their ability to reduce mortality. The study was supported in part by the Agency for Healthcare Research and Quality (HS16901).

See "Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure," by Rishi J. Desai, MS, PhD, Carol M. Ashton, MD, MPH, Anita Deswal, MD, MPH, and others in Pharmacoepidemiology and Drug Safety 21, pp. 233-240, 2012.


Page last reviewed January 2013
Internet Citation: Four drugs to treat chronic heart failure found similarly effective: Comparative Effectiveness Research. January 2013. Agency for Healthcare Research and Quality, Rockville, MD.


The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care